CoChat

Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation

Open access
Jaeger, Alex M., Stopfer, Lauren, Lee, Sunmin, Gaglia, Giorgio, Sandel, Demi, Santagata, Sandro, Lin, Nancy U., Trepel, Jane B., White, Forest, Jacks, Tyler, Lindquist, Susan, Whitesell, Luke · 2019 · Clinical Cancer Research
Cited by 61

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Purpose: Despite the accumulation of extensive genomic alterations, many cancers fail to be recognized as “foreign” and escape destruction by the host immune system. Immunotherapies designed to address this problem by directly stimulating immune effector cells have led to some remarkable clinical outcomes, but unfortunately, most cancers fail to respond, prompting the need to identify additional immunomodulatory treatment options. Experimental Design: We elucidated the effect of a novel treatment paradigm using sustained, low-dose HSP90 inhibition in vitro and in syngeneic mouse models using genetic and pharmacologic tools. Profiling of treatment-associated tumor cell antigens was performed using immunoprecipitation followed by peptide mass spectrometry. Results: We show that sustained, low-level inhibition of HSP90 both amplifies and diversifies the antigenic repertoire presented by tumor cells on MHC-I molecules through an IFNγ-independent mechanism. In stark contrast, we find that acute, high-dose exposure to HSP90 inhibitors, the only approach studied in the clinic to date, is broadly immunosuppressive in cell culture and in patients with cancer. In mice, chronic non-heat shock–inducing HSP90 inhibition slowed progression of colon cancer implants, but only in syngeneic animals with intact immune function. Addition of a single dose of nonspecific immune adjuvant to the regimen dramatically increased efficacy, curing a subset of mice receiving combination therapy. Conclusions: These highly translatable observations support reconsideration of the most effective strategy for targeting HSP90 to treat cancers and suggest a practical approach to repurposing current orally bioavailable HSP90 inhibitors as a new immunotherapeutic strategy. See related commentary by Srivastava and Callahan, p. 6277

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-0596

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 61

Metadata

Authors
Jaeger, A. M., Stopfer, L., Lee, S., Gaglia, G., Sandel, D., Santagata, S., Lin, N. U., Trepel, J. B., White, F., Jacks, T., Lindquist, S., & Whitesell, L.
Venue
Clinical Cancer Research
Published
2019-11-01
Volume
25
Issue
21
Pages
6392-6405
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2952596195
Cited by
61
References
18
FWCI
2.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0596
The paper
Jaeger, A. M., Stopfer, L., Lee, S., Gaglia, G., Sandel, D., Santagata, S., Lin, N. U., Trepel, J. B., White, F., Jacks, T., Lindquist, S., & Whitesell, L. (2019). Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0596

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.